Moreover, also MHY2256, a SIRT1/2 inhibitor has been shown to reduce viability of both p53 wild-type or mutant colorectal cancer lines (HCT116, HT29 and DLD-1) (Kim et al., 2020). Here, TP53 is linked to colorectal cancer.